ClinicalTrials.gg
RecruitingNCT04647292EPICS-PilotUpdated Jul 11, 2024

European Blood Pressure Intensive Control After Stroke

A Phase 2 interventional study of anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration and Standard of Care Blood Pressure Management with Antihypertensives in Ischemic Stroke and Transient Ischemic Attack, sponsored by University College Dublin. Recruiting at 1 site in Ireland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by University College Dublin · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Ischemic Stroke with a site in Ireland — 3 open to participants now, 3 under way, none of them phase 3. Ischemic Stroke · Ireland.

Started
2024
with 1 other
Phase 2
2 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
University College Dublin

Among the 10 studies in Ischemic Stroke with a site in Ireland, this one is one of 2 that started in 2024, is one of 2 in phase 2, and was the 7th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

3 of the 10 studies in Ischemic Stroke with a site in Ireland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Ireland have not opened yet or have stopped. Only those recruiting at a site in Ireland →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Ischemic Stroke with a site in Ireland, or all of them as a file.
02

Study summary

Stroke is the third most common cause of death worldwide and the leading cause of disability. High blood pressure is an important risk factor for stroke. Lowering a person's blood pressure reduces the risk of future stroke or heart attack, and current guidelines recommend treatment to a target of \<130mmHg for secondary prevention.

Home blood pressure measurement and telemonitoring are acceptable to patients, but there is uncertainty over the use of out of office blood pressure measurements in stroke patients in guidelines.

This is a study designed to establish the feasibility of a larger clinical trial, comparing home blood pressure monitoring, telemonitoring and medication titration with standard care. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.

Read the detailed description

Background:

Stroke is the third leading cause of global death, the leading cause of acquired disability and contributes substantially to dementia, cognitive decline, and healthcare costs. Global epidemiological studies such as INTERSTROKE and the Global Burden of Disease study estimated that hypertension is the leading modifiable risk factor for stroke, with a population attributable risk of approximately 50%. Recurrent vascular events (stroke, coronary events, vascular death) cause significant morbidity in ischaemic stroke survivors, affecting approximately 30% at 5 years.

High rates of failure to achieve guideline BP targets (\<130mmHg) are reported in clinical practice for patients following ischaemic stroke or TIA. Home blood pressure measurement and telemonitoring is recognised as acceptable to patients from previous studies, and some trials have noted a significant reduction in BP at 12 months. The latest ESO guidelines note continued uncertainty over the use of out-of-office blood pressure measurements for adult patients with ischaemic stroke or TIA due to insufficient data.

This trial will recruit patients with recent stroke/TIA events with systolic BP ≥140 mmHg and randomise them to standard of care or home BP monitoring with telemonitoring and medication titration. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.

Aim:

The aim is to conduct an initial pilot randomised trial in Ireland and European centres involved in the European Stroke Organisation Trials Alliance. This feasibility study will assess key design aspects and establish trial governance, data management, and procedures in preparation for a larger definitive trial.

Methods:

Design: Prospective, open-label, blinded endpoint assessed (PROBE) randomised, parallel group pilot/feasibility clinical trial, comparing BP patient self-measurement and telemonitoring with office-based monitoring (standard of care) for improved BP control after ischaemic stroke/TIA.

03

Conditions studied

  • Ischemic Stroke
  • Transient Ischemic Attack

Keywords

  • ischemic stroke
  • transient ischemic attack
  • blood pressure
  • hypertension
  • recurrence
  • prognosis
  • prevention
  • randomized control trial
  • myocardial infarction
  • vascular events
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥40
  2. Ischaemic stroke1, high-risk , proven by imaging (brain CT/MRI)
  3. Living at home and independent (walking without the aid of another person, but may have some help for daily activities)
  4. SBP≥140mmHg at entry (average of 2 measures, seated, in the same arm, after resting alone in office for 10 minutes)
  5. Qualifying event between 30 days and 1 year of randomisation
  6. (eGFR) greater than or equal to 50ml/min/m2 (within 3 months of randomisation)
  7. Medically-stable and capable of participating in a randomised trial, including home BP measures, in the opinion of the study physician
  8. Willing to provide (no surrogate consent will apply)

Exclusion criteria

Exclusion Criteria:

  1. SBP \<110mmHg after 3 minutes of standing or other to intensive SBP lowering in opinion of treating clinician (eg. Orthostatic symptoms, syncope or pre syncope, recurrent falls)
  2. Qualifying stroke due to intracerebral haemorrhage (ICH), cardio-embolism or other defined causes (eg. dissection, endocarditis, other specified)
  3. Severe stenosis or occlusion of large cranio-cervical artery (>70% stenosis/occlusion of cervical carotid, vertebral, or Circle of Willis artery)
  4. Unlikely to comply with study procedures due to severe or fatal comorbid illness (eg. dementia, active , severe frailty) or other factor (eg. inability to travel)
  5. Pregnancy or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Home Blood Pressure Measurement, Telemonitoring and Medication titration

    Medication titration to guideline SBP \<130mmHg

    Other: anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration

  • Active comparator
    Control Group: Standard of Care Blood Pressure Management

    Standard of Care Management by GP/physician to SBP \<130mmHg by current European Stroke Organisation, American Stroke Association and UK NICE guidelines

    Other: Standard of Care Blood Pressure Management with Antihypertensives

Interventions

  • Otheranti-hypertensive, home blood pressure measurement, telemonitoring and medication titration

    A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy. Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly.

  • OtherStandard of Care Blood Pressure Management with Antihypertensives

    Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP \<130mmHg.

06

What researchers measure

Primary outcomes

  1. Difference in mean SBP

    The difference in mean SBP between both groups, at 12 months (or last trial visit)

    Time frame: 12 months (or last trial visit)

Secondary outcomes

  1. Proportions of patients assigned to each arm successfully reaching guideline-based target (SBP<130mmHg) at end of trial visit

    Time frame: 12 months (or last trial visit)

  2. Time in guideline-based target range

    Proportion of SBP measures \<130 during trial participation

    Time frame: 12 months (or last trial visit)

  3. Time taken to reach target

    Time taken to reach target SBP\<130mmHg

    Time frame: 12 months (or last trial visit)

  4. Difference in mean diastolic blood pressure (DBP) between groups

    Time frame: 12 months (or last trial visit)

  5. Change in SBP/DBP from baseline to end-of-trial

    Time frame: 12 months (or last trial visit)

  6. Time to first composite major adverse cardiovascular event (MACE), and to each component of the composite, stratified as fatal, non-fatal and total

    MACE defined as all recurrent stroke, myocardial infarction, cardiac arrest

    Time frame: 12 months (or last trial visit)

  7. All-cause fatality

    Time frame: 12 months (or last trial visit)

  8. Comparison of disability in each intervention arm assessed by modified Rankin score

    Shift analysis and proportion with no, mild, or moderate disability, Rankin score 0-3

    Time frame: 12 months (or last trial visit)

  9. Number of dose-titrations required

    Time frame: 12 months (or last trial visit)

  10. Time required per follow up visit

    Time frame: 12 months (or last trial visit)

  11. Number of patients lost to follow-up

    Time frame: 12 months (or end of trial visit)

  12. Number of serious adverse events

    Difference in proportion of patients with serious adverse events

    Time frame: 12 months (or last trial visit)

  13. Number of pre-specified adverse events

    Time frame: 12 months (or last trial visit)

  14. Change in health related quality of life

    Change in EQ5D-5L score (5 domains assessed with scores of 1-5 ranking the severity of impairment, with higher scores indicating poorer quality of life) at last follow-up compared with baseline

    Time frame: 12 months (or last trial visit)

  15. Change in cognition

    Change in Montreal cognitive assessment score (range 0-30) at last follow-up compared with baseline score. A lower score indicates greater cognitive impairment.

    Time frame: 12 months (or last trial visit)

  16. Qualitative patient feedback obtained via workshops and questionnaires

    Time frame: 12 months (or last trial visit)

Other outcomes

  1. Number of patients who do not complete the study due to tolerability or other issues

    Patients who are not retained in the study will give an insight into anticipated retention in the Phase 3 trial and sample size considerations.

    Time frame: 12 months (or end of trial visit)

  2. Ability of sites to rapidly identify eligible patients from clinics and stroke units

    The inclusion of prevalent cases already attending stroke clinics or discharged from stroke units within the last year is an important design feature, aimed to rapidly accrue patients into the trial and thus to maximise the duration of follow-up within the terms allowed by funders. This outcome will be judged on the basis of qualitative feedback from participating sites.

    Time frame: 12 months (or end of trial visit)

  3. Feasibility of home blood pressure (BP) measures and telemonitoring

    This outcome will be judged on the basis of qualitative feedback from participants and the the proportions of participants adhering to the use of home blood pressure diaries.

    Time frame: 12 months (or end of trial visit)

  4. Compliance with telemonitoring and feasibility of remote (phone) visits

    The feasibility of remote (phone) visits will be assessed by the proportion of patients adhering to participation in remote visit consultations

    Time frame: 12 months (or end of trial visit)

  5. Feasibility of remote BP titration

    The feasibility of titration of BP based on prescriptions to pharmacies in response to BP telemonitoring

    Time frame: 12 months (or end of trial visit)

  6. Barriers to participation of women

    Qualitative review to improve the design of a future Phase 3 trial with the aim of reducing barriers to women

    Time frame: 12 months (or end of trial visit)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Saiz LC, Gorricho J, Garjon J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2022 Nov 18;11(11):CD010315. doi: 10.1002/14651858.CD010315.pub5. PubMed 36398903 ↗

Individual participant data

Plan to share: Undecided — The investigators are open to considering requests for collaborative projects.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2025, 19 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 19 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2020
First posted
Nov 30, 2020
StartActual
May 2, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Mar 2026
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04647292
Collaborators
St Vincent's University Hospital, Ireland, Cork University Hospital, Tallaght University Hospital, HRB Stroke Trials Network Ireland, National University of Ireland, Galway, Ireland, Mater Misericordiae University Hospital, St. James's Hospital, Ireland, Connolly Hospital Blanchardstown
Responsible party
Sponsor
First posted
Nov 30, 2020
Start date
May 2, 2024
Primary completion
Dec 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jul 11, 2024

Study contacts

Katrina Tobin
Contact
katrina.tobin@ucd.ie
+353 1 716 4576

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion